Trial (author) | Year | Treatment arms | Treatment-emergent adverse events, % (n/N) | Death, % (n/N) | Discontinuation due to adverse events, % (n/N) | Non-severe infections, % (n/N) | Serious adverse events, % (n/N) |
---|---|---|---|---|---|---|---|
MEASURE-1 (Baeten) [25] | 2015 | SEC | 68.3 (170/249) | 0 (0/249) | 1.2 (3/249) | 30.1 (75/249) | 2.0 (5/249) |
 | PBO | 55.7 (68/122) | 0.8 (1/122) | 4.1 (5/122) | 12.3 (15/122) | 4.1 (5/122) | |
MEASURE-2 (Baeten) [25] | 2015 | SEC | 61.4 (89/145) | 0.7 (1/145) | 4.8 (7/145) | 31.7 (46/145) | 5.5 (8/145) |
 | PBO | 63.5 (47/74) | 0 (0/74) | 5.4 (4/74) | 27.0 (20/74) | 4.1 (3/74) | |
MEASURE-3 (Pavelka) [26] | 2017 | SEC | 45.3 (68/150) | 0 (0/150) | 0 (0/150) | N/A | 0.7 (1/150) |
 | PBO | 44 (33/75) | 0 (0/75) | 0 (0/75) | N/A | 1.3 (1/75) | |
MEASURE-4 (Kivitz) [27] | 2018 | SEC | 56.2 (131/233) | 0 (0/233) | 1.3 (3/233) | N/A | 1.7 (4/233) |
 | PBO | 54.7 (64/117) | 0 (0/117) | 0.9 (1/117) | N/A | 3.4 (4/117) | |
COAST-V (van der Heijde) [28] | 2018 | IXE | 42.7 (70/164) | 0 (0/164) | 1.8 (3/164) | 20.1 (33/164) | 1.2 (2/164) |
 | PBO | 39.5 (34/86) | 0 (0/86) | 0 (0/86) | 15.1 (13/86) | 0 (0/86) | |
COAST-W (Deodhar) [29] | 2019 | IXE | 62.3 (132/212) | 0.5 (1/212) | 6.1 (13/212) | 26.9 (57/212) | 3.3 (7/212) |
 | PBO | 49.0 (51/104) | 0 (0/104) | 1.9 (2/104) | 9.6 (10/104) | 4.8 (5/104) |